Heart Disease Trial, Recruiting NCT05426083 Sponsor: University of Minnesota Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT05426083
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 75 years old
  • People who have a severe form of cardiogenic shock (when the heart cannot pump enough blood) that requires a specific heart-lung support machine called VA-ECMO, as determined by their treating medical team
  • People whose blood pressure is maintained above a certain level (MAP greater than 65 mmHg) while on fewer than three medications to support blood pressure or heart function at the time of agreeing to participate
  • People whose cardiogenic shock was caused by a heart attack, confirmed by a procedure that examines the heart's blood vessels (coronary angiography), during the same hospital stay

Who may not be able to join:

  • People who need VA-ECMO support due to a serious blood infection (sepsis), a blood clot in the lungs (pulmonary embolism), heart or breathing failure related to COVID-19, or severe failure of the right side of the heart caused by a specific lung condition (idiopathic pulmonary arterial hypertension)
  • People whose cardiogenic shock was caused by something other than a heart attack
  • People already known to have severe, long-standing heart failure (classified as the most severe stage) who were being considered for, or have previously had, a mechanical heart pump (LVAD) or heart transplant before being placed on VA-ECMO
  • People whose blood pressure remains dangerously low (MAP below 65 mmHg) even while on three blood pressure or heart-support medications
  • People with a moderate to severe leaking heart valve (aortic regurgitation), as this is a safety concern with VA-ECMO
  • People with a moderate to severe narrowing of the main heart valve (aortic stenosis), as this makes certain procedures used in the trial unsafe
  • People who are actively experiencing bleeding that requires ongoing blood transfusions
  • People showing signs of reduced blood supply to the lower limbs (ischemic lower extremities)
  • People whose VA-ECMO circuit shows signs of blood clotting or buildup inside the tubing
  • People showing signs of a serious body-wide infection (sepsis or septic shock)
  • People whose heart scans (echocardiography) show a blood clot inside the left chamber of the heart, as this makes certain procedures used in the trial unsafe

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Demetris Yannopoulous, MD, University of Minnesota

Phone: 612-625-5949

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
4 August 2022
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Pressure-volume loops at the highest level of VA-ECMO support and the lowest level of VA-ECMO support.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov